Tecan and Monash Antibody Technologies Facility announce a partnership to create one of the largest, most sophisticated monoclonal antibody production systems in the world today
Plans are already underway to develop the system, which will be based around multiple, integrated liquid handling workstations and will fully automate all the stages of the production process.
The importance of monoclonal antibody production is reflected by the breadth of use, which includes research applications, diagnostic applications and successful use as therapeutic agents.
In the research world, the use of monoclonal antibodies has proven crucial to the understanding of a myriad of physiological processes, and has led to new approaches in the treatment of diseases with great unmet clinical need.
In the medical world, they are currently used as diagnostic agents to detect cancers or infectious diseases; as vaccines to boost the body's immune response; and as therapeutics, to target cancerous cells or to decrease the body's own immune response in diseases such as rheumatoid arthritis and multiple sclerosis.
The MATF is one of the only high throughput production facilities in the world offering custom-made, high-affinity monoclonal antibodies.
The new system will increase the production capacity at MATF from original estimates of 500 panels of novel antibodies a year to potentially 5,000, helping to alleviate the bottleneck of antibody supply experienced by many researchers working on protein function and physiological processes.
The new system, partially funded by the Victoria state government and Monash University, National Collaborative Research Infrastructure Strategy and the Australian Stem Cell Centre, is the first major step towards an extensive assay development programme planned for 2008, which will further strengthen Monash University's rising profile as a centre of excellence in the international medical research community.
Alan Sawyer, director of MATF, who was instrumental in establishing a similar world-renowned facility for the European Molecular Biology Laboratory (EMBL), said: "Probably the main bottleneck in biomedical sciences right now is a lack of affinity reagents like antibodies - we wanted to remove that bottleneck and open up new ways for investigators and pharmaceutical companies to think about doing science.
"This is a colossal step towards accomplishing that".
Deputy director Michael Spiegel added: "Tecan's involvement on this project has far exceeded a simple supplier/client relationship.
"It has embraced this challenging project becoming a fundamental partner, contributing innovative project design, competent expertise and a flexible working attitude".
Carl Severinghaus, senior vice president at Tecan, said: "We are delighted to be co-developing this exciting new system with the MATF and look forward to working together on this as well as any future endeavours".
Tecan's team of application specialists and engineers will build the new system at the company's headquarters in Mannedorf, Switzerland, ready for installation at the MATF in April 2008.
